Immatics N.V. (NASDAQ:IMTX - Get Free Report)'s share price reached a new 52-week high on Thursday . The stock traded as high as $11.25 and last traded at $11.02, with a volume of 101634 shares changing hands. The stock had previously closed at $10.83.
Analyst Upgrades and Downgrades
Several research analysts have weighed in on the stock. Guggenheim assumed coverage on shares of Immatics in a report on Thursday, September 18th. They issued a "buy" rating and a $16.00 price target on the stock. Zacks Research raised shares of Immatics from a "strong sell" rating to a "hold" rating in a report on Monday. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immatics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $13.67.
Read Our Latest Analysis on IMTX
Immatics Trading Up 1.5%
The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -16.94 and a beta of 1.22. The company's 50-day moving average is $6.96 and its 200-day moving average is $5.85.
Immatics (NASDAQ:IMTX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.28). The firm had revenue of $6.48 million for the quarter, compared to analyst estimates of $13.05 million. Immatics had a negative return on equity of 15.60% and a negative net margin of 59.29%. Equities research analysts forecast that Immatics N.V. will post -0.72 EPS for the current year.
Institutional Trading of Immatics
A number of hedge funds have recently added to or reduced their stakes in the stock. T. Rowe Price Investment Management Inc. boosted its position in Immatics by 38.4% in the first quarter. T. Rowe Price Investment Management Inc. now owns 14,677,003 shares of the company's stock valued at $66,194,000 after buying an additional 4,072,226 shares in the last quarter. Vestal Point Capital LP boosted its position in Immatics by 14.6% in the first quarter. Vestal Point Capital LP now owns 7,192,700 shares of the company's stock valued at $32,439,000 after buying an additional 917,700 shares in the last quarter. Sofinnova Investments Inc. boosted its position in Immatics by 44.1% in the second quarter. Sofinnova Investments Inc. now owns 2,240,528 shares of the company's stock valued at $12,054,000 after buying an additional 686,224 shares in the last quarter. Wasatch Advisors LP boosted its position in Immatics by 35.9% in the second quarter. Wasatch Advisors LP now owns 785,154 shares of the company's stock valued at $4,224,000 after buying an additional 207,491 shares in the last quarter. Finally, Aberdeen Group plc boosted its position in Immatics by 107.1% in the first quarter. Aberdeen Group plc now owns 719,586 shares of the company's stock valued at $3,245,000 after buying an additional 372,207 shares in the last quarter. Institutional investors and hedge funds own 64.41% of the company's stock.
About Immatics
(
Get Free Report)
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immatics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immatics wasn't on the list.
While Immatics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.